Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF PILL
Set alert
15.21 USD -0.44 -2.81%
At close
15.25 +0.04 +0.26%
Pre-market · Nov 2, 7:00 AM ET
15.02 Day range 15.84
7.75 52-week range 24.15
- YTD
- +23.66%
- 1 year
- +71.09%
- Open
- 15.62
- Prev close
- 15.65
- Mkt cap
- 31.53M
- Vol
- 238.29K
- Avg vol
- 52.14K
- EPS
- 0.35853
- P/E
- 42.42
- Div yield
- 0.00%
More statistics
- Low
- 15.02
- High
- 15.84
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 8.83
- 200-d avg
- 7.64
1M chart
Signals (7)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 27, 2026 | 5 days ago |
| SMA: Bearish | Oct 23, 2026 | 1 week ago |
| SMA: Bullish | Oct 20, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 20, 2026 | 1 week ago |
| SMA: Bearish | Oct 12, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 9, 2026 | 3 weeks ago |
| RSI: Oversold | Oct 6, 2026 | 3 weeks ago |
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 13.48
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 8.83
- 200-day average
- 7.64
About Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF
The fund invests at least 80% of its net assets in financial instruments, that, in combination, provide 3X daily leveraged exposure to the index, consistent with the fund's investment objective. The index is a modified equal-weighted index that is designed to measure performance of the stocks comprising the S&P Total Market Index that are classified in the GICS pharmaceuticals sub-industry. The fund is non-diversified.
News
- Trump Unveils 'Great Healthcare Plan,' Takes Aim At PBM 'Kickbacks'
- Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily'
- Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms
- Mark Cuban Exposes How Wholesalers Force Pharmacies Into Near-Exclusive Deals, Detailing PBMs' 'Stranglehold' On Drug Pricing
- Mark Cuban Says Cutting PBM Fees Won't Reduce Pharmaceutical R&D Funding: 'Manufacturers Can Sell To Us For More'
- Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains'
- Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies
- Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare'
- Trump's Drug Price Order Hits PBMs Hardest: CVS, Cigna, UNH In Focus As Experts Highlight 'Racket,' Pricing Distortion
- Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies
Your note
Sign in to keep a note on PILL — it syncs with the Stock Master app.